| August 7, 2014 | ISSUE NUMBER 363 VOL 4 |
Technology
Apple or Big Pharma? Who Will Lead in Wearable Healthcare Devices?
Apple's iWatch may not have happened yet, but eyes are still fixed on the company to see what it does in the healthcare wearables space. And in this sector, the question might not be whether Apple can compete with Big Pharma, but whether Big Pharma will be able to play with Apple ...Read more
POP
Propel your education forward with the University of Florida’s online MS in Pharmaceutical Outcomes and Policy. Earn your master’s in pharmacy in as little as 2 years with collaborative online classes and flexible scheduling for working professionals. Focus on one of our three specializations, boost your high-level career opportunities, and explore topics affecting today’s pharmaceutical and regulatory environment.
 Learn more and apply by August 15
Finance and Investment
US and France Establish Partnership Payout for the Best in Start-Up Innovations
The Galien Foundation and the French government investment agency UBIFRANCE have partnered to establish UBISTART, a transatlantic payout for the best in start-up innovations. William Looney reports
...Read more
The lifecycle of a new product is shorter, more contested, full of regulatory delays, and beset by a challenging access and reimbursement environment. Learn how to wrest maximum value from every stage of the lifecycle – from access to acquisition to adherence–  by downloading this eBook.
Event
Risk and Innovation in Biopharma: A CEO Perspective
At the recent NYBIO conference, Dr. Sam Waksal, CEO of New York-based biopharma Kadmon, spoke about the importance of imagination for innovation; current business risks in the industry; and applying understanding to the concept of Big Data
...Read more
Are Your Patient Access Solutions Performing up to Your Expectations?
On Demand webcast
To Registere at:  www.pharmexec.com
Pricing and Reimbursement
Managing High-Priced, US Biotech Rxs in Canada
As the “Saga of Sovaldi” continues to unfold in the U.S., it’s pretty clear the situation will only continue to deteriorate. However, as you look north of the American border, it’s striking how Canadian healthcare entities are managing a similar Sovaldi situation, as well as the other new, high cost, American biotech products that are beginning to appear there. Tom Norton reports
...Read more
|
|
|
|
 //Anne Whitaker, President, North America pharmaceuticals, at Sanofi, is leaving the company to become President and CEO of Synta Pharmaceuticals (Lexington, MA), effective September 2.//INC Research (Raleigh, NC) announced the appointment of Jan Schreur as the company’s Senior Vice President, Human Resources.//Akers Biosciences, Inc. (Thorofare, NJ) appointed Nicolas Daurel as Vice President of International Sales and Marketing for Europe, Middle East and Africa.//Intarcia Therapeutics, Inc. (Boston, MA) announced the appointment of Sunita Zalani, Ph.D., as Vice President and Global Head of Regulatory Affairs and Quality.//
|
|
|
|
|
|
 |
|
| |
 |
|
 |
The FDA Safety & Innovation Act (FDASIA) was signed into law two years ago. Where has the most progress been made in implementation?
|
|
|
|
